Dr. Fonseca on FDA Approval of Daratumumab Triplets in Multiple Myeloma

Rafael Fonseca, MD, discusses frontline multiple myeloma treatment patternsПодробнее

Analysis of Different Clinical Scenarios using Daratumumab | Rafael Fonseca, MD | Ash 2021Подробнее

Next steps in myeloma: quadruplets, immunotherapy, and replacing transplantПодробнее

When will the daratumumab triplet combination be approved for multiple myeloma?Подробнее

Dr. Landgren on Daratumumab Triplet in Relapsed MyelomaПодробнее

Dr. Wong Discusses the FDA Approval of Elotuzumab Triplet in MyelomaПодробнее

Dr. Berdeja on FDA Approval of Frontline Daratumumab Plus VMP in Multiple MyelomaПодробнее

FDA Approval of Frontline Daratumumab Plus VMP in Multiple MyelomaПодробнее

What is Multiple Myeloma? | Dr. Rafael Fonseca, M.D. | The Patient StoryПодробнее

All About Darzalex (daratumumab)Подробнее

Dr. Rafael Fonseca: A discussion about the utility of gene expression in Multiple MyelomaПодробнее

The importance of anti-CD38 monoclonal antibodies for multiple myelomaПодробнее

Daratumumab in multiple myeloma: an overview of 3 key trialsПодробнее

Dr. Palumbo on Significance of Daratumumab Triplet in Multiple MyelomaПодробнее

Dr. Fonseca on FISH Testing in Patients With MyelomaПодробнее

Practical Information on Immunotherapy UseПодробнее

MRD Tests and Applications — Rafael Fonseca, MD | MCRT Webcast August 29 (2/4)Подробнее

MCRT Phoenix 2017: The Basics of Myeloma Genetics by Rafael Fonseca, MDПодробнее

What does the FDA approval of MRD testing for myeloma mean for patients and drug development?Подробнее